Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.

Journal of clinical pathology - 1 Jan 2016

Richman Susan D, Adams Richard, Quirke Phil, Butler Rachel, Hemmings Gemma, Chambers Phil, Roberts Helen, James Michelle D, Wozniak Sue, Bathia Riya, Pugh Cheryl, Maughan Timothy, Jasani Bharat

Abstract excerpt

INTRODUCTION: Molecular characterisation of tumours is increasing personalisation of cancer therapy, tailored to an individual and their cancer. FOCUS4 is a molecularly stratified clinical trial for patients with advanced colorectal cancer. During an initial 16-week period of standard first-line chemotherapy, tumour tissue will undergo several molecular assays, with the results used for cohort allocation, then...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to England

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Diagnostic Techniques

Share to Observer Variation

Share to Patient Selection

Share to Precision Medicine

Share to Predictive Value of Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 26350752
DOI: 10.1136/jclinpath-2015-203097
PMCID: PMC4717430

Genes

BRAF
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.PMID 26350752Read ↗

FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing.Semantic proximity Read ↗

Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders.Semantic proximity Read ↗

Prevalence of Mutations in Common Tumour Types in Northern England and Comparable Utility of National and International Trial FindersSemantic proximity Read ↗

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.Semantic proximity Read ↗

Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.Semantic proximity Read ↗

Intra-tumoral Heterogeneity of<i>KRAS</i>and<i>BRAF</i>Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample TestingSemantic proximity Read ↗

Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial.Semantic proximity Read ↗

Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in Oncology patients treated in a specialist cancer centre with prospective validation within clinical trial dataSemantic proximity Read ↗

Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue.Semantic proximity Read ↗

Clinical validation of the 50 gene AmpliSeq Cancer Panel V2 for use on a next generation sequencing platform using formalin fixed, paraffin embedded and fine needle aspiration tumour specimens.Semantic proximity Read ↗

Designing personalised cancer treatments.Semantic proximity Read ↗

Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.